Roivant Sciences (ROIV) Minority Interest (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Minority Interest came in at $765.0 million in Q1 2026, up 53.13% YoY from $499.6 million in Q1 2025, and up 8.52% on a QoQ basis from $705.0 million in Q4 2025.
Roivant Sciences (ROIV) Minority Interest (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Minority Interest data on file, last reported at $765.0 million in Q1 2026.
- Quarterly Minority Interest rose 53.13% year-over-year to $765.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $765.0 million (up 53.13% YoY) and the FY2026 annual result came in at $765.0 million, up 53.13% from the prior year.
- Minority Interest rose to $765.0 million in Q1 2026, from $705.0 million in the prior quarter.
- In the past five years, Minority Interest ranged from a high of $765.0 million in Q1 2026 to a low of $22.5 million in Q1 2022.
- A 5-year average of $443.1 million and a median of $446.5 million in 2023 frame the typical range for Minority Interest.
- Annual changes were most pronounced in 2023 — Minority Interest jumped 1900.0% — and 2024, when it declined 29.97%.
- Tracing ROIV's Minority Interest over 5 years: stood at $353.5 million in 2022, then jumped by 39.96% to $494.8 million in 2023, then decreased by 29.97% to $346.5 million in 2024, then jumped by 103.46% to $705.0 million in 2025, then gained by 8.52% to $765.0 million in 2026.
- The last three Minority Interest figures came in at $765.0 million (Q1 2026), $705.0 million (Q4 2025), and $443.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 690.60 Mn |
| Mar 31, 2026 | 765.04 Mn |
| Dec 31, 2025 | 704.97 Mn |
| Sep 30, 2025 | 443.13 Mn |
| Jun 30, 2025 | 470.27 Mn |
| Mar 31, 2025 | 499.59 Mn |
| Dec 31, 2024 | 346.50 Mn |
| Sep 30, 2024 | 427.09 Mn |
| Jun 30, 2024 | 459.98 Mn |
| Mar 31, 2024 | 479.95 Mn |
| Dec 31, 2023 | 494.82 Mn |
| Sep 30, 2023 | 377.10 Mn |
| Jun 30, 2023 | 423.41 Mn |
| Mar 31, 2023 | 449.82 Mn |
| Sep 30, 2022 | 353.55 Mn |
| Jun 30, 2022 | 371.28 Mn |
| Mar 31, 2022 | 22.49 Mn |
| Dec 31, 2021 | 22.49 Mn |
| Sep 30, 2021 | 22.49 Mn |
| Jun 30, 2021 | 22.49 Mn |